ArticleThe mental health clinician2022
Positioning psychiatric pharmacists to improve mental health care.
Article in The mental health clinician, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- The role of board-certified psychiatric pharmacists in United States foster care: Opportunities to optimize psychotropic medication use.The mental health clinician · 2026Article
- Board-certified psychiatric pharmacists in substance use disorder treatment: Integration, services, and outcomes across care settings.The mental health clinician · 2026Review
- Comparison of pharmacist-led outpatient depression management to current prescriber-led depression management.The mental health clinician · 2025Article
- Pharmaceutical solutions implemented to improve mental health care pathways: a systematic realist review protocol.BMJ open · 2025Article
- Evaluation of workload among Board-Certified Psychiatric Pharmacists in the United States.The mental health clinician · 2025Article
- Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review.The mental health clinician · 2025Review
- Potential changes impacting psychiatric pharmacy by 2030.The mental health clinician · 2025Article
- Pharmacist-social worker interprofessional relations and education in mental health: a scoping review.PeerJ · 2024Article
- Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital.The mental health clinician · 2023Article
- Psychotropic stewardship: Advancing patient care.The mental health clinician · 2023Article
- Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effects.Therapeutic advances in drug safety · 2023Article
- Ambitious AAPP vision necessitates bold actions.The mental health clinician · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric pharmacy continues to grow and look to the future with a focus on helping individuals recover from mental health and substance use disorders. The American Association of Psychiatric Pharmacists (AAPP) considers Board Certified Psychiatric Pharmacist (BCPP) the gold standard credential that all psychiatric pharmacists should attain to demonstrate specialized knowledge and expertise in psychiatry. BCPPs are part of collaborative interprofessional teams and practice in hospitals, clinics, and diverse health systems. Two out of 3 BCPPs practicing in clinics have prescriptive authority. BCPPs improve access, safety, medication adherence, and therapeutic outcomes. Every person with a mental health and substance use disorder should have access to a BCPP providing comprehensive medication management (CMM) and psychotropic stewardship aimed at improving population health. BCPPs are in demand owing to their expertise. AAPP envisions growth and expansion of the BCPP role in many areas including coordinating psychiatric transitions of care and telehealth services, managing long-acting injectable medication clinics, providing pharmacogenomic consultation, conducting clozapine and lithium monitoring, managing medications for substance use disorders, leading medication groups, CNS drug development, research, and provider education. To prepare the workforce, colleges and schools of pharmacy should hire BCPPs for optimal curriculum development, and each student pharmacist should have an opportunity to develop a therapeutic alliance with a person recovering from psychiatric illness. Postgraduate year (PGY) 1 residencies should offer learning experiences in psychiatric pharmacy to prepare residents to enter an expanded number of PGY2 psychiatric pharmacy residencies, ultimately earning their BCPP and being well positioned to improve mental health care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.